Abstract

BackgroundEarly diagnosis and treatment reduces HIV-1-related mortality, morbidity and size of viral reservoirs in infants infected perinatally. Commercial molecular tests enable the early diagnosis of infection in infants but the high cost and low sensitivity with dried blood spots (DBS) limit their use in sub-Saharan Africa.ObjectivesTo develop and validate a sensitive and cheap qualitative proviral DNA PCR-based assay for early infant diagnosis (EID) in HIV-1-exposed infants using DBS samples.Study designChelex-based method was used to extract DNA from DBS samples followed by a nested PCR assay using primers for the HIV-1 integrase gene. Limit of detection (LoD) was determined by Probit regression using limiting dilutions of newly produced recombinant plasmids with the integrase gene of all HIV-1 subtypes and ACH-2 cells. Clinical sensitivity and specificity were evaluated on 100 HIV-1 infected adults; 5 infected infants; 50 healthy volunteers; 139 HIV-1-exposed infants of the Angolan Pediatric HIV Cohort (APEHC) with serology at 18 months of life.ResultsAll subtypes and CRF02_AG were amplified with a LoD of 14 copies. HIV-1 infection in infants was detected at month 1 of life. Sensitivity rate in adults varied with viral load, while diagnostic specificity was 100%. The percentage of HIV-1 MTCT cases between January 2012 and October 2014 was 2.2%. The cost per test was 8-10 USD which is 2- to 4-fold lower in comparison to commercial assays.ConclusionsThe new PCR assay enables early and accurate EID. The simplicity and low-cost of the assay make it suitable for generalized implementation in Angola and other resource-constrained countries.

Highlights

  • HIV-1 mother-to-child-transmission (MTCT) is the main mode of infection among the pediatric population and is disproportionately affecting children in impoverished countries

  • The considerable uptake of HIV-1 DNA molecular tests is driven by the lower costs compared with quantitative assays along with their good sensitivity when performed on blood microsamples or dried blood spots (DBS) [7]

  • Two HIV-1 DNA assays are commercially available for early infant diagnosis (EID) using DBS: the COBAS1 AmpliPrep/COBAS1 TaqMan1 HIV-1 Qualitative Test (Roche Molecular System Inc., Branchburg, NJ), which recently replaced the Roche Amplicor1 DNA test v1.5, and the RealTime HIV-1 Qualitative Test (Abbott Molecular, Des Plaines, IL) [8]

Read more

Summary

Introduction

HIV-1 mother-to-child-transmission (MTCT) is the main mode of infection among the pediatric population and is disproportionately affecting children in impoverished countries. Two HIV-1 DNA assays are commercially available for EID using DBS: the COBAS1 AmpliPrep/COBAS1 TaqMan HIV-1 Qualitative Test (Roche Molecular System Inc., Branchburg, NJ), which recently replaced the Roche Amplicor DNA test v1.5, and the RealTime HIV-1 Qualitative Test (Abbott Molecular, Des Plaines, IL) [8] These assays are highly sensitive but require sophisticated instrument platforms whose cost with related equipment (e.g. centrifuge; biosafety cabinet; freezer) can range from about US$ 100,000 to more than US$ 200,000. Commercial molecular tests enable the early diagnosis of infection in infants but the high cost and low sensitivity with dried blood spots (DBS) limit their use in sub-Saharan Africa

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call